Skip to main content

Table 3 Promter Hypermethylation and cervical cancer survival

From: Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome

   Alive Dead Hazard Ratio§ 95%CI
Total loci 0 9 2 1.00
  1 6 9 0.75 0.14–4.00
  2 13 19 1.04 0.20–5.50
  ≥3 11 13 1.07 0.19–5.92
CDH1 + 18 27 0.69 0.29–1.63
  - 21 16 1.00
DAPK + 19 18 0.53 0.23–1.19
  - 20 25 1.00
RARB + 8 16 1.66 0.80–3.46
  - 31 27 1.00
HIC1 + 7 8 1.67 0.69–4.04
  - 32 35 1.00
FHIT + 3 6 1.18 0.38–3.66
  - 36 37 1.00
RASSF1A + 5 1 2.02 0.16–25.08
  - 34 42 1.00
APC + 4 5 0.70 0.21–2.41
  - 35 38 1.00
CDKN2A + 2 5 1.64 0.51–5.26
  - 37 38 1.00
MGMT + 0 4 2.30 0.46–11.45
  - 39 39 1.00
BRCA1 + 0 5 3.05 0.72–12.93
  - 39 38 1.00
  1. Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups)